From: "Annie Lennon" <alouiselennon@gmail.com>
To: "Ravimiamet" <info@ravimiamet.ee>
Subject: Medscape Interview: AI in Medicine
Date: Tue, 19 May 2026 09:12:00 +0300
Message-ID: <CAEYDeuvmuZUsZ7qDEOyXnS7wsVMsmBPoH7KjSKz3P=7nmNesXQ@mail.gmail.com>
MIME-Version: 1.0
Content-Type: multipart/alternative;
	boundary="----=_NextPart_000_014D_01DCEDE1.5B519510"
Received-SPF: None (mail3.rit.ee: no sender authenticity  information available from domain of  postmaster@mail-dl1-f49.google.com) identity=helo;  client-ip=74.125.82.49; receiver=mail3.rit.ee;  envelope-from="alouiselennon@gmail.com";  x-sender="postmaster@mail-dl1-f49.google.com";  x-conformance=spf_only
Authentication-Results-Original: mail3.rit.ee; spf=Pass smtp.mailfrom=alouiselennon@gmail.com; spf=None smtp.helo=postmaster@mail-dl1-f49.google.com; dkim=pass (signature verified) header.i=@gmail.com; dmarc=pass (p=none dis=none) d=gmail.com
IronPort-SDR: 6a0bff8a_JEVbOtAaeBfdNv7QoOv+SxBVZpoQMbxCqfNBc7QSSZuMpA+ 9ov2tLWroHd5oIJsGgaU39WfaJmIwIJVblDUTbg==
X-MS-Exchange-Organization-ExpirationStartTime: 19 May 2026 06:13:32.1651
 (UTC)
X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit
X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000
X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit
X-MS-Exchange-Organization-Network-Message-Id: 26beb292-97b9-4803-812b-08deb56dc0aa
X-EOPAttributedMessage: 0
X-EOPTenantAttributedMessage: 8fe098d2-428d-4bd4-9803-7195fe96f0e2:0
X-MS-Exchange-Organization-MessageDirectionality: Incoming
X-MS-PublicTrafficType: Email
X-MS-TrafficTypeDiagnostic: DU2PEPF00028D0F:EE_|AS8PR02MB9019:EE_|AS2PR02MB9740:EE_
X-MS-Exchange-Organization-AuthSource: DU2PEPF00028D0F.eurprd03.prod.outlook.com
X-MS-Exchange-Organization-AuthAs: Anonymous
X-MS-Office365-Filtering-Correlation-Id: 26beb292-97b9-4803-812b-08deb56dc0aa
X-MS-Exchange-AtpMessageProperties: SA|SL
X-DisclaimerOO: 1
X-MS-Exchange-Organization-SCL: -1
X-Microsoft-Antispam: BCL:0;ARA:13230040|704160911799003|82310400026|7093399015|8096899003|55112099003|16102099003|18002099003|19002099003|56012099003|11063799003;
X-Forefront-Antispam-Report: CIP:213.184.59.150;CTRY:EE;LANG:en;SCL:-1;SRV:;IPV:NLI;SFV:NSPM;H:mail3.rit.ee;PTR:mail3.rit.ee;CAT:NONE;SFS:(13230040)(704160911799003)(82310400026)(7093399015)(8096899003)(55112099003)(16102099003)(18002099003)(19002099003)(56012099003)(11063799003);DIR:INB;
X-MS-Exchange-CrossTenant-OriginalArrivalTime: 19 May 2026 06:13:31.5863
 (UTC)
X-MS-Exchange-CrossTenant-Network-Message-Id: 26beb292-97b9-4803-812b-08deb56dc0aa
X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2
X-MS-Exchange-CrossTenant-AuthSource: DU2PEPF00028D0F.eurprd03.prod.outlook.com
X-MS-Exchange-CrossTenant-AuthAs: Anonymous
X-MS-Exchange-CrossTenant-FromEntityHeader: Internet
X-MS-Exchange-Transport-CrossTenantHeadersStamped: AS8PR02MB9019
X-MS-Exchange-Transport-EndToEndLatency: 00:00:02.1528491
X-MS-Exchange-Processed-By-BccFoldering: 15.21.0048.002
X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(4710137)(4717077)(4999163)(920097)(930201)(20251009189)(140003);
X-Microsoft-Antispam-Message-Info: =?us-ascii?Q?BnxgV8fYbB/oeb4n8Mn0CkbfgJ0Q4Q8rFYFeoNdVLAJBYpOTDLoAXZs+17Az?=
 =?us-ascii?Q?J5f4EziMkJNcZuEJte2GW8mabkMe5LUc3el527j8bKl0CBx6THglrczDDTus?=
 =?us-ascii?Q?j/Uz4NCksaD9/BKhIUySp1mlbs6J+zlCAnUA6guDQlIO5Pbs0/4lr4MzwbM3?=
 =?us-ascii?Q?glFhWxjxnUCoprDowlrAWvDZAmFq8HnmyFw14YjCOtqTdlMSd+bXff9aOMbe?=
 =?us-ascii?Q?RmA5P+H59vlF/TzpvSWRuSAK9/GU/Prpzsn8xX8ES0ir2zWTPH+MdkYXgAKj?=
 =?us-ascii?Q?jzs46xTMd3EKrJnd0ODKJ+btGHv31lvn9x9nG9XkLyuhMC3UKTCFl69c8uGU?=
 =?us-ascii?Q?ACdRzTBILvgPTLCH6vshZJ32fmVxbwLp8LRMME3bedu80I92EhlfEwTp1/Td?=
 =?us-ascii?Q?f23D19j26yZ8zE4VS049E0TjlE+PA1zsK7QPlZtaQVh2E0PNHOSkhhKAj0Rm?=
 =?us-ascii?Q?tmt4Zd1tYZOHKKbwdPbWAnlFgLDDlf+no8DmaNdmONoS0z6DIFuNMB3AdSpv?=
 =?us-ascii?Q?6PrmOJV+PjapECU1MZoNcMuYvNEr80S03IAd2f1iE378P9DegoBb7RV/laMu?=
 =?us-ascii?Q?9RD/xKQu2/OxnHVoDa0aO7yZwgLDb5R32ja9wVK1hVW4/dVZuQ5NjCZI8X4b?=
 =?us-ascii?Q?gEh3F7arKqP8ekDCW4Kqvpv4jGfLvFHKT8+Bzro4Sqs6foBsnCHYz9sfVZjp?=
 =?us-ascii?Q?oEQiyrV+V6jvkOfYtgWS4nb2GoKsPsIouEzpQWxc1ukJNjo5T10
	xg6WYeZLq?=
 =?us-ascii?Q?VzTqse+S90rAJcqqsGYq66wl/4uNfAeqf2ODPDD9CDISi1zfZKNjQj4CKLgR?=
 =?us-ascii?Q?Q+3jHYLQoIhAm3AlcaR0EOto9iclPrsXoQJydqN9guo5inJeD8UduLiZA/mC?=
 =?us-ascii?Q?p3jlP6Bn3TSGyZnWxndycRLEv216AexIvtWPHJPxmB9e3IDFv628u32qxxQd?=
 =?us-ascii?Q?Li78nnipmgGb/TUwkit95ztMJmKiwTFT8YKWVrR+gpDfLn6usmKl7rjLynBQ?=
 =?us-ascii?Q?aOIDfvGHFHm1/cDSonAPhxwrbcOMVNVyarffBf7IIPQneInuUBlfqXxFHf6R?=
 =?us-ascii?Q?mPf4TeBuMl/iDq731ZxEVZtcbu1kysOpm1mh1S3NaK0yKcU7w0pxv3Mwi+48?=
 =?us-ascii?Q?s/dDeEaTsulWxZ0zCss2yiKxRQ0BO79bvFMskMVY4V9ocMXe/uvSfni7M2cC?=
 =?us-ascii?Q?MzMu3Zz3So5f3j6KgTPJJgfydt40FIO/wv11SxwU5Or2dUngi9sVD0crToa9?=
 =?us-ascii?Q?2sHu5b8I1Dv3P/F/EDqGiULW/jwOZGGClnzqRRbv62kxDLKWkcfnV18751cw?=
 =?us-ascii?Q?TmdWPBJsvo3K54q8rYbwxv/bBncfRFaDNBfzJxeqME08xWZM9/+QjTLTeIK/?=
 =?us-ascii?Q?FT/M/lLVbNQwnfUrPY8DT2FY0JPlM0MmRRNAN2YmWrFUYvEq1+FUCBvsUhfu?=
 =?us-ascii?Q?l+jST60k6X/4A0MYcNv8FaUDeKCKIQVDqKklrvOWxwOGeG3u139waQwZw5pV?=
 =?us-ascii?Q?5LDn1Pp2cJux14tzOj8drCKrAgZyU1untKSzR
	rX6+0f/qxDNrXFCxtmIkJmt?=
 =?us-ascii?Q?Ay45rBg0yyyHJ/+zd1ZFlyyM5uN7Xiwj5KgDTMZ9Hifi1sWuwrbUuKvhbznR?=
 =?us-ascii?Q?ymMctmt3DBcsNYMsZ9atg5S1+xqV4PSd7sDFxKGFpNIyChsPereZZNR/JEVx?=
 =?us-ascii?Q?yFHo0+kCYNT9Ur/Rtq29e7+1sTi2UmiuvtDxgDVIoMRP5ADSclAuun+KxCCQ?=
 =?us-ascii?Q?YEPqdCFa/nlZqc/6vxN8HCmM6myLG5f0ZawQF0XJAaMNW3796SjyFBmgPJm5?=
 =?us-ascii?Q?YbjQ8VNvpYwdxRsAm9UuH8z7fxCFQ8CoYwdXcouHZujxjio2db373YxnADCK?=
 =?us-ascii?Q?Z4tpIM2da5KnlNWEBqOKmz+n5O6pwiqkdNQCptJelFH+QUpyYZl8S+pZgezF?=
 =?us-ascii?Q?xLHpVS183fq0+wYpGUje9ZFxLfEUFXhvNZ8+0aR5NzA10AH/P6inEusD+qGZ?=
 =?us-ascii?Q?/Gs5BUJDo3ukKp4cTnHC3Og8Z0yArdh1CYxMGN7WAFwb9ebV2bWMgwcbgct1?=
 =?us-ascii?Q?YsSFEWUMeNnOFJ++bSZSngfhjyBttC1aOjOxwXoTaXqLmh/iLIaWOdVU21V0?=
 =?us-ascii?Q?eTCEIzErfEr++DQCWsF75knvc8TLZq+7WkjXnTzVdVOuVHrfJKWuJdY0FP8u?=
 =?us-ascii?Q?c70hy8fsiEx0NinHRqvEYzSsp0LG3Mej1XlTGWDWVCWKSWcDdoCmZiWkf4tK?=
 =?us-ascii?Q?LkGna7b4eBlfwORkWOsJmLawRkI3fWrDyoZel3xMVnkvo1slcTTF/vsQ+V22?=
 =?us-ascii?Q?jxFMVLJ4bSxKcEg9axmwnPa
	8vCdFIXBNBlzjU0spIDkJ9tf8kZKF3MosJAjs?=
 =?us-ascii?Q?NsrBGhl23ghdXZYyDRbZEzpJeYRt5uvrSc1gg4zKtXQmuy1cNGWu/4tg569K?=
 =?us-ascii?Q?0PYxVMdg4nRi9PuVUtN/JFSY5QHUofIW6boaw5htocPqqFP5ov+/V7OtvPsZ?=
 =?us-ascii?Q?orlf1cGBLFvtvqzf8l51oaGuuzXeuJ8p/fTM1CjbjXbRV65eEIZM8yiFqrWQ?=
 =?us-ascii?Q?MAwmVzHmNo1KPSR0yxV81lfu29U2JmReHp2p1C4RV6eb9sISBDY36K/5AjBL?=
 =?us-ascii?Q?X73G8onBthqbyXm6d4GUHO5pRrdavbKpT13N7uWKrDmD/y5aaYrm+WGYRk4b?=
 =?us-ascii?Q?7uCOUMt3BRWRkktr6JLh2+lG4kHQcmDcbVfZ/+7euxdkFx8mS0HWIxya8fSi?=
 =?us-ascii?Q?dKGw2/qFSHUHQvRt4C4+DDWoYC7668GhhFoLJKqpjRYDjOy/h5YcUL7aVhhm?=
 =?us-ascii?Q?rrDtfUVgiNJ10/EQwWBLlnSwn0ntm+k6SJ3iLe07mm9d6XPKYOCgQp/920Uz?=
 =?us-ascii?Q?9Y2Q0E1hpjj3X9dhqaM+AGh0OlPFmu4odH/bvccEUumI+KfCmu29Xa/JfKH4?=
 =?us-ascii?Q?cvBJngAB1SmZtMcXMENi6HMv8BodU3H4sMVOTONkpmBkQOrPVII+7Wwv4/i2?=
 =?us-ascii?Q?NmenQddcuDwKXGjl4dw6GP5cU8voL7SMS2l6oEFfbqYk/Q1rfv3PNTR1ueAE?=
 =?us-ascii?Q?jmHhptRMBdm2Hg+4N7Ag9S3YYt46TCyE3p9i9KJGM4K0uhj91llUNjU0QWdN?=
 =?us-ascii?Q?eErgWoD6F
	GqHCi/0sqiaRgafBb+ZgR1p9NMeEooeLHqeT7T8cnyIm60TDuCD?=
 =?us-ascii?Q?LG2Vcs6BJBNq4eDujyVv9nvfUf/DVb6ReRNtoKO5K/0kA67eUefMv4K1mGWF?=
 =?us-ascii?Q?GDUTIpD0n5RFrD2lNYhSeYTxYTEYLP6v+rcO0LSbfgUElxD292exYyB3IGyd?=
 =?us-ascii?Q?TkNHVUERQMHuG3ClYv9sEyGvu95bzao2qPnc/UueGlfgNDifSIeEWOO2Wd45?=
 =?us-ascii?Q?pgE6SohH2/Ru4CqRjhU6tqjoPK/1ccpV8EiKuLHNBk+vNyTqzY+OB8bkt7nU?=
 =?us-ascii?Q?Siq/qKjD7v0HTfesbJBNAnunfzQYFXOiAy7LxFEbgciZ9i+8Lqny7Zsgl4NI?=
 =?us-ascii?Q?DlUnEuOlS37NOxdV09S/dEeNHA0oyNMLjVZFv5qmLN5Go2ObV3DgGECtYcNz?=
 =?us-ascii?Q?IIjkNdvfu0SWhycixulrXhoeBMWUauDNpUvFTxeublqM0TzL/krLXE2h2ile?=
 =?us-ascii?Q?lMFfouAApiqiiZ+Etqi7U/xkeF1KiW20Aj1yb6Qkp5fX5vF3b8bPTNjvI3JZ?=
 =?us-ascii?Q?NZpGH5o3y84QqkfxnwBt52bGit4Odd5yXn/TRghFPNSrDj6xSlzEzIHyx1YP?=
 =?us-ascii?Q?EPYcQRsU80UoUE6LovXsCIBIhofQsPI=3D?=
Thread-Index: AQFyBVKGAzhKkpde/mmVZC0XAQw2WQ==
X-MS-Exchange-ExternalInOutlookResult: NotEnabled
Content-Language: et
x-ms-exchange-organization-originalclientipaddress: 213.184.59.150
x-ms-exchange-organization-originalserveripaddress: 10.167.242.23
X-OlkEid: 000000004C30E2D3CD34B4428531CBEB8A7CAB89070034AD76187591974DBF6C4F76951C873A0100020000000000B04CDEF8D3227A448511457FBBCE9C8700000000097B0000B4A9C8E0F29A8B41ACA9194E0CF73A3D

This is a multipart message in MIME format.

------=_NextPart_000_014D_01DCEDE1.5B519510
Content-Type: text/plain;
	charset="utf-8"
Content-Transfer-Encoding: 8bit


Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.

To whom this may concern,


Hope all is well! My name is Annie Lennon, and I'm a freelance medical 
journalist at Medscape, one of Europe's leading healthcare websites intended 
for healthcare professionals.

I'm currently working on a feature piece looking at whether declining trust 
in doctors is pushing some patients to rely more heavily on AI tools for 
self-diagnosis and self-medication — and what that means for patient safety. 
I was wondering if I could discuss the topic with you. These are the kinds 
of questions I have in mind:


1) How much evidence is there that some patients distrust doctors or formal 
healthcare pathways and are turning to AI instead?

2) Are patients using AI tools to self-diagnose and then find ways to access 
medicines without medical supervision?

3) How does this behavior affect patient safety? What are the positive and 
negative effects?

4) Given that AI is here to stay and patients will continue using it, what 
can clinicians and health systems do to keep people safe?


It'd be great to receive any comments back by Friday morning, May 22nd.

Much appreciated and best wishes,

Annie Lennon

------=_NextPart_000_014D_01DCEDE1.5B519510
Content-Type: text/html;
	charset="utf-8"
Content-Transfer-Encoding: quoted-printable

<html><head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; =
charset=3Dutf-8">
</head>
<body>
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" =
cellpadding=3D"0" align=3D"left" width=3D"100%" =
style=3D"width:100.0%;mso-cellspacing:0cm;mso-yfti-tbllook:1184; =
mso-table-lspace:2.25pt;mso-table-rspace:2.25pt;mso-table-anchor-vertical=
:paragraph;mso-table-anchor-horizontal:column;mso-table-left:left;mso-pad=
ding-alt:0cm 0cm 0cm 0cm">
<tbody>
<tr =
style=3D"mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes">
<td style=3D"background:#910A19;padding:5.25pt 1.5pt 5.25pt 1.5pt"></td>
<td width=3D"100%" =
style=3D"width:100.0%;background:#FDF2F4;padding:5.25pt 3.75pt 5.25pt =
11.25pt; word-wrap:break-word" cellpadding=3D"7px 5px 7px 15px" =
color=3D"#212121">
<div>
<p class=3D"MsoNormal" =
style=3D"mso-element:frame;mso-element-frame-hspace:2.25pt; =
mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element=
-anchor-horizontal: column;mso-height-rule:exactly">
<span style=3D"font-size:9.0pt;font-family: &quot;Segoe =
UI&quot;,sans-serif;mso-fareast-font-family:&quot;Times New =
Roman&quot;;color:#212121"><strong>T=C3=A4helepanu!
</strong>Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.<br>
Tundmatu saatja korral palume linke ja faile mitte =
avada.<o:p></o:p></span></p>
</div>
</td>
</tr>
</tbody>
</table>
<div>
<div dir=3D"ltr">
<div><font color=3D"#000000" face=3D"Calibri, Helvetica, sans-serif">To =
whom this may concern,&nbsp;</font></div>
<div><font color=3D"#000000" face=3D"Calibri, Helvetica, =
sans-serif"><br>
</font></div>
<div><font color=3D"#000000" face=3D"Calibri, Helvetica, =
sans-serif">Hope all is well!&nbsp;</font>My name is Annie Lennon, and =
I'm a freelance medical journalist at&nbsp;Medscape, one of Europe's =
leading healthcare websites intended for healthcare =
professionals.&nbsp;<font color=3D"#000000" face=3D"Calibri, Helvetica, =
sans-serif"><br>
<br>
</font>I'm currently working on a feature piece looking at whether =
declining trust in doctors is pushing some patients to rely more heavily =
on AI tools for self-diagnosis and self-medication =E2=80=94 and what =
that means for patient safety. I was wondering if I could
 discuss the topic with you. These are the kinds of questions I have in =
mind:&nbsp;</div>
<div><br>
</div>
<blockquote style=3D"margin:0px 0px 0px =
40px;border-width:medium;border-style:none;border-color:currentcolor;padd=
ing:0px">
<div>1)&nbsp;<span =
style=3D"background-color:transparent;font-family:Arial,sans-serif;white-=
space:pre-wrap">How much evidence is there that some patients distrust =
doctors or formal healthcare pathways and are turning to AI =
instead?</span></div>
<div><br>
</div>
<div>2) Are patients using AI tools to self-diagnose and then find ways =
to access medicines without medical supervision?&nbsp;</div>
<div><br>
</div>
<div>3) How does this behavior affect patient safety? What are the =
positive and negative effects?</div>
<div><br>
</div>
<div>4) Given that AI is here to stay and patients will continue using =
it, what can clinicians and health systems do to keep people safe?</div>
</blockquote>
<div><br>
</div>
<div>
<div>It'd be great to receive any comments back by&nbsp;<b>Friday =
morning, May 22nd</b>.&nbsp;</div>
<div dir=3D"auto"><br>
</div>
<div dir=3D"auto">Much appreciated and best wishes,</div>
</div>
<div>
<div><br>
</div>
<div>Annie Lennon</div>
</div>
</div>
</div>
</body>
</html>

------=_NextPart_000_014D_01DCEDE1.5B519510--